InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” Immune-Mediated Inflammatory Diseases Market – (By Treatment Type (Traditional Drugs, Biologic Therapies, Novel Therapies), Indication (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis, Others), By Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Immune-Mediated Inflammatory Diseases Market is predicted to grow with a CAGR of 7.10% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2889
Immune-mediated inflammatory diseases (IMIDs) comprise a group of interrelated disorders characterized by common inflammatory mechanisms driven by immune system dysregulation, although their precise etiology remains unclear. These conditions arise from an overactive or improperly functioning immune response and are associated with heightened risks of morbidity, mortality, and long-term organ damage.
The global prevalence of autoimmune disorders has been increasing steadily, driven by a combination of genetic susceptibility and modifiable lifestyle factors such as sedentary behavior and suboptimal dietary habits. This rising incidence is fueling growth in the global IMID therapeutics market, as there is an expanding need for effective treatment options and innovative therapeutic solutions to manage these complex, chronic conditions.
List of Prominent Players in the Immune-Mediated Inflammatory Diseases Market:
- Novartis AG
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
- Abbvie Inc.
- Merck & Co Inc.
- Zydus Group
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- AstraZeneca
- Ampio Pharmaceuticals Inc.
- Eli Lilly
- Akorn Incorporated
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Growth Drivers:
The global market for immune-mediated inflammatory diseases (IMIDs) is expected to achieve sustained growth, primarily driven by the rising prevalence of chronic conditions such as psoriasis, Crohn’s disease, and rheumatoid arthritis. Expansion is further supported by the increasing adoption of advanced biologic therapies that provide targeted treatment options. In addition, enhanced patient access through diverse distribution channels—including specialty clinics, retail pharmacies, and digital health platforms—is contributing to market momentum.
Challenges:
Despite promising growth prospects, the market faces notable challenges. A shortage of healthcare professionals skilled in administering complex biologic therapies can limit treatment accessibility. Furthermore, adverse effects associated with certain treatments—such as dermatological reactions and complications from immunosuppressive drugs—may affect patient adherence and clinical outcomes. The COVID-19 pandemic also disrupted market activity, as healthcare systems deferred non-urgent procedures and redirected resources to pandemic response efforts, resulting in temporary declines in market performance.
Regional Insights:
North America is projected to maintain its leadership position in the global IMID market in terms of revenue, supported by a high prevalence of autoimmune disorders, growing demand for biologic therapeutics, and robust research and development initiatives targeting novel treatments.
The approval and commercialization of innovative therapies, alongside increased utilization of immunosuppressive agents, continue to drive regional growth. Meanwhile, the Asia-Pacific region is experiencing accelerated expansion, fueled by greater awareness of autoimmune diseases, ongoing improvements in healthcare infrastructure, and advances in diagnostic and treatment technologies for inflammatory conditions.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2889
Recent Developments:
- In July 2024, AbbVie announced that the European Commission has sanctioned SKYRIZI® (risankizumab) for the treatment of elderly individuals with moderately to severely active ulcerative colitis (UC) who have experienced an inadequate response to, lost response to, or exhibited intolerance to conventional or biologic therapies.
Segmentation of Immune-Mediated Inflammatory Diseases Market-
By Indication-
- Asthma,
- Chronic Obstructive Pulmonary Diseases (COPD)
- Inflammatory Bowel Disease (IBD)
- Systemic Lupus Erythematosus (SLE)
- Rheumatoid Arthritis (RA)
- Psoriasis
- Others
By Treatment Type-
- Traditional Drugs
- Biologic Therapies
- Novel Therapies
By Route of Administration-
- Oral
- Parenteral
- Others
By End-Users-
- Hospitals
- Specialty Clinics
- Others
By Distribution Channel-
- Hospital Pharmacy
- Retail Pharmacy
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
